Page 1686 - Williams Hematology ( PDFDrive )

1660 Part XI: Malignant Lymphoid Diseases Chapter 100: Mantle Cell Lymphoma 1661

20. Hoster E, Dreyling M, Klapper W, et al: German Low Grade Lymphoma Study Group and ASCT in mantle cell lymphoma: Final analysis of the MCL Younger Trial of
(GLSG); European Mantle Cell Lymphoma Network: A new prognostic index (MIPI) the European Mantle Cell Lymphoma Network (MCL net). (ASH Annual Meeting
for patients with advanced-stage mantle cell lymphoma. Blood 111:558, 2008. Abstracts) Blood 120:151, 2012.
21. Hoster E, Klapper W, Hermine O, et al: Confirmation of the mantle-cell lymphoma 45. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemo-
International Prognostic Index in randomized trials of the European Mantle-Cell Lym- therapy followed by autologous stem cell transplantation in first remission significantly
phoma Network. J Clin Oncol 32:1338, 2014. prolongs progression-free survival in mantle cell lymphoma: Results of a prospective
22. Pott C, Schrader C, Gesk S, et al: Quantitative assessment of molecular remission after randomized trial of the European MCL Network. Blood 105:2677, 2005.
high-dose therapy with autologous stem cell transplantation predicts long-term remis- 46. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy and autologous
sion in mantle cell lymphoma. Blood 107:2271, 2006. stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB
23. Pott C, Hoster E, Delfau-Larue MH, et al: Molecular remission is an independent 59909. J Clin Oncol 27:6101, 2009.
predictor of clinical outcome in patients with mantle cell lymphoma after combined 47. van ‘t Veer MB, de Jong D, MacKenzie M, et al: High-dose Ara-C and beam with auto-
immunochemotherapy: A European MCL intergroup study. Blood 115:3215, 2010. graft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol
24. Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al: Prognostic role of SOX11 144:524, 2009.
in a population-based cohort of mantle cell lymphoma. Blood 119:4215, 2012. 48. Geisler CH, Kolstad A, Laurell A, et al: Nordic Lymphoma Group: Nordic MCL2 trial
25. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle- update: Six-year follow-up after intensive immunochemotherapy for untreated mantle
cell lymphoma. J Clin Oncol 27:1209, 2009. cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very
26. Leitch HA, Gascoyne RD, Chhanabhai M, et al: Limited-stage mantle-cell lymphoma. long survival but late relapses do occur. Br J Haematol 158:355, 2012.
Ann Oncol 10:1555, 2003. 49. Delarue R, Haioun C, Ribrag V, et al: CHOP and DHAP plus rituximab followed by
27. Engelhard M, Unterhalt M, Hansmann M, et al: Follicular lymphoma, immunocytoma, autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from
and mantle cell lymphoma: Randomized evaluation of curative radiotherapy in limited the Groupe d’Etude des Lymphomes de l’Adulte. Blood 121:48, 2013.
stage nodal disease. Ann Oncol 19(Suppl 4):418, 2008. 50. de Guibert S, Jaccard A, Bernard M, et al: Rituximab and DHAP followed by intensive
28. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial therapy with autologous stem-cell transplantation as first-line therapy for mantle cell
for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. lymphoma. Haematologica 91:425, 2006.
Hematol Oncol 7:365, 1989. 51. Magni M, Di Nicola M, Carlo-Stella C, et al: High-dose sequential chemotherapy and
29. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: A 10-year
entities: Mantle cell lymphoma and marginal zone lymphoma (including mucosa-as- update of the R-HDS regimen. Bone Marrow Transplant 43:509, 2009.
sociated lymphoid tissue and monocytoid B-cell categories): A Southwest Oncology 52. Le Gouill S, Thieblemont C, Oberic L, et al: Rituximab maintenance versus wait and
Group study. Blood 85:1075, 1995. watch after four courses of R-DHAP followed by autologous stem cell transplantation in
30. Hiddemann W, Unterhalt M, Herrmann R, et al: Mantle-cell lymphomas have more previously untreated young patients with mantle cell lymphoma: First interim analysis
widespread disease and a slower response to chemotherapy compared with follicle- of the phase III prospective Lyma Trial, a Lysa Study. (ASH Annual Meeting Abstracts)
center lymphomas: Results of a prospective comparative analysis of the German Blood 124:146, 2014.
Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922, 1998. 53. Romaguera JE, Fayad LE, McLaughlin P, et al: Phase I trial of bortezomib in combina-
31. Ghielmini M, Schmitz SF, Cogliatti S, et al: Effect of single-agent rituximab given at the tion with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytara-
standard schedule or as prolonged treatment in patients with mantle cell lymphoma: bine for untreated aggressive mantle cell lymphoma. Br J Haematol 151:47, 2013, 2010.
A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705, 54. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD alternating with high
2005. dose cytarabine and methotrexate for the initial treatment of patients with mantle cell
32. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol
for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not pre- 156:346, 2012.
dictive of progression-free survival. J Clin Oncol 20:1288, 2002. 55. Bernstein SH, Epner E, Unger JM, et al: A phase II multicenter trial of hyperCVAD
33. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophos- MTX/Ara-C and rituximab in patients with previously untreated mantle cell lym-
phamide, doxorubicin, vincristine, and prednisone significantly improves response and time to phoma; SWOG 0213. Ann Oncol 24:1587, 2013.
treatment failure, but not long-term outcome in patients with previously untreated mantle cell 56. Hoster E, Metzner B, Forstpointner R, et al: Autologous stem cell transplantation and
lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma addition of rituximab independently prolong response duration in advanced stage
Study Group (GLSG) J Clin Oncol 23:1984, 2005. mantle cell lymphoma. (ASH Annual Meeting Abstracts) Blood 114:880, 2009.
34. Herold M, Haas A, Doerken B, et al: Immunochemotherapy (R-MCP) in advanced 57. Hoster E, Geisler GH, Doorduijn JK, et al: Role of high-dose cytarabine and total body
mantle cell lymphoma is not superior to chemotherapy (MCP) alone—50 months irradiation conditioning before autologous stem cell transplantation in mantle cell lym-
update of the OSHO phase III study (OSHO#39). Ann Oncol 19:abstr 12, 2008. phoma—A comparison of Nordic MCL2, HOVON 45, and European MCL Younger
35. Kenkre VP1, Long WL, Eickhoff JC, et al: Maintenance rituximab following induc- Trials. (ASH Annual Meeting Abstracts) Blood 122:3367, 2013.
tion chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot 58. Kolstad A, Laurell A, Jerkeman M, et al: Nordic MCL3 study: 90Y-ibritumomab-tiux-
study from the Wisconsin Oncology Network. Leuk Lymphoma 52:1675, 2011. etan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
36. Gressin R, Caulet-Maugendre S, Deconinck E, et al: Evaluation of the (R)VAD+C reg- Blood 123(19):2953, 2014.
imen for the treatment of newly diagnosed mantle cell lymphoma. Combined results 58A. Chang JE, Li H, Smith MR, et al: Phase 2 study of VcR-CVAD with maintenance ritux-
of two prospective phase II trials from the French GOELAMS group. Haematologica imab for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group
95:1350, 2010. study (E1405). Blood 123(11):1665–1673, 2014.
37. Sachanas S, Pangalis GA, Vassilakopoulos TP, et al: Combination of rituximab with 59. Forstpointner R, Dreyling M, Repp R, et al: German Low-Grade Lymphoma Study
chlorambucil as first line treatment in patients with mantle cell lymphoma: A highly Group: The addition of rituximab to a combination of fludarabine, cyclophosphamide,
effective regimen. Leuk Lymphoma 52:387, 2011. mitoxantrone (FCM) significantly increases the response rate and prolongs survival as
38. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with man- compared with FCM alone in patients with relapsed and refractory follicular and mantle
tle-cell lymphoma. N Engl J Med 367:520, 2012. cell lymphomas: Results of a prospective randomized study of the German Low-Grade
39. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus cyclophosphamide, Lymphoma Study Group. Blood 104:3064, 2004.
doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttri- 60. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective
um-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Coopera- and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-
tive Oncology Group Study E1499. J Clin Oncol 30:3119, 2012. Hodgkin’s lymphoma. J Clin Oncol 23:3383, 2005.
40. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus 61. Robinson KS, Williams ME, van der Jagt RH, et al: Phase II multicenter study of ben-
CHOP plus rituximab as first-line treatment for patients with indolent and mantle- damustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non
cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. -Hodgkin’s lymphoma. J Clin Oncol 26:4473, 2008.
Lancet 381:1203, 2013. 62. Weide R, Hess G, Köppler H, et al: High anti-lymphoma activity of bendamustine/
41. Visco C, Finotto S, Zambello R, et al: Combination of rituximab, bendamustine, and mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lym-
cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for inten- phomas and mantle cell lymphomas. A multicenter phase II study of the German Low
sive regimens or autologous transplantation. J Clin Oncol 31:1442, 2013. Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 48:1299, 2007.
42. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall 63. Gironella M, Lopez A, Merchan B, et al: Rituximab plus gemcitabine and oxaliplatin
survival in patients with indolent or mantle cell lymphoma: A systematic review and as salvage therapy in patients with relapsed/refractory mantle-cell lymphoma. (ASH
meta-analysis. J Natl Cancer Inst 99:706, 2004. Annual Meeting Abstracts) Blood 120:1627, 2012.
43. Flinn IW, van der Jagt R, Kahl BS, et al: Randomized trial of bendamustine-rituximab 64. Tam CS, Bassett R, Ledesma C, et al: Mature results of the M. D. Anderson Cancer Center
or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144, 2009.
study. Blood 123:2944, 2014. 65. Le Gouill S, Kröger N, Dhedin N, et al: Reduced-intensity conditioning allogeneic stem
44. Hermine O, Hoster E, Walewski J, et al: Alternating courses of 3x CHOP and 3x DHAP cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter expe-
plus rituximab followed by a high dose ARA-C containing myeloablative regimen and rience. Ann Oncol 23:2695, 2012.
autologous stem cell transplantation (ASCT) increases overall survival when compared 66. Hamadani M, Saber W, Ahn KW, et al: Allogeneic hematopoietic cell transplantation for
to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy chemotherapy-unresponsive mantle cell lymphoma: A cohort analysis from the center

Kaushansky_chapter 100_p1653-1662.indd 1661 9/18/15 5:06 PM